RET and lung adenocarcinoma: For instance, several tyrosine kinase inhibitors, targeting EGFR, ALK, RET receptor tyrosine kinase (RET), and proto-oncogene tyrosine-protein kinase ROS (ROS1), are the standard of care for lung adenocarcinoma (LUAD) patients carrying corresponding molecular mutations [1,2,3,4].